These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8367739)

  • 1. Cost-effectiveness--can it be measured?
    Bohn RL; Avorn J
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):20-3. PubMed ID: 8367739
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with prophylaxis in Sweden.
    Nilsson IM
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.
    Roosendaal G; Lafeber F
    N Engl J Med; 2007 Aug; 357(6):603-5. PubMed ID: 17687136
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience with prophylaxis in Germany.
    Schramm W
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):12-5. PubMed ID: 8367737
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresolved issues in prophylaxis.
    Brown SA; Aledort LM; Astermark J; Berntorp E; van den Berg M; Blanchette V; Donfield S; Gringeri A; Hilgartner M; Kulkarni R; Leissinger C; Negrier C; Nuss R; Petterson H; Petrini P; Poulios N; Schramm W;
    Haemophilia; 2002 Nov; 8(6):817-21. PubMed ID: 12410654
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
    Thornburg CD; Pipe SW
    Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
    [No Abstract]   [Full Text] [Related]  

  • 12. Arthropathy in children with severe hemophilia A.
    Soreff J; Blombäck M
    Acta Paediatr Scand; 1980 Sep; 69(5):667-73. PubMed ID: 6785993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High potency factor VIII concentrates: value not proved?
    Cash JD
    BMJ; 1991 Sep; 303(6803):633-4. PubMed ID: 1932909
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylactic infusion regimens in the management of hemophilia.
    Ljung RC
    Thromb Haemost; 1999 Aug; 82(2):525-30. PubMed ID: 10605746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophilia treatment. Immune tolerance induction: prospective clinical trials.
    Hay CR
    Haematologica; 2000 Oct; 85(10 Suppl):52-5; discussion 55-6. PubMed ID: 11187872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDC/hemophilia study targets blood safety and joint disease. Centers for Disease Control and Prevention.
    Colvin R
    Common Factor; 1997 Nov; (No 11):7, 16. PubMed ID: 11364846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can haemophilic arthropathy be prevented?
    Ljung RC
    Br J Haematol; 1998 May; 101(2):215-9. PubMed ID: 9609513
    [No Abstract]   [Full Text] [Related]  

  • 18. Factor VIII: maximal benefit?
    Nour-Eldin F
    Eur J Med; 1992 Apr; 1(1):55-7. PubMed ID: 1341979
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of musculo-skeletal complications of hemophilia.
    Srivastava RK; Sinha RS; Mehrotra V
    Indian Pediatr; 1984 Dec; 21(12):965-70. PubMed ID: 6442986
    [No Abstract]   [Full Text] [Related]  

  • 20. Prophylaxis in children with hemophilia: is it the optimal treatment?
    Lusher JM
    Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.